Denali Therapeutics, Inc.

Denali Therapeutics, Inc.

Denali Therapeutics, Inc.

Overview
Date Founded

2013

Headquarters

161 Oyster Point Boulevard,San Francisco, CA 94080

Type of Company

Public

Employees (Worldwide)

261

Industries

Biotechnology
IT Consulting & Services
Pharmaceuticals
Medical Support Services

Company Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Denali Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Operating Officer & Founder

Treasurer, Chief Financial & Accounting Officer

Chief Scientific Officer

Chief People Officer

Chief Medical Officer & Head-Development

Chief Technical & Manufacturing Officer

Contracts Coordinator

Director

Senior Project Manager

Board of Directors

Venture Partner at ARCH Venture Partners

President at Stanford University

Co-Founder at Vir Biotechnology, Inc.

General Partner at Google Ventures

Former President & Chief Executive Officer at Illumina, Inc.

Director at NGINX Software, Inc.

Former Head, Product Portfolio Management at Genentech, Inc.

Co-Founder at Denali Therapeutics, Inc.

Chief Executive Officer at Kallyope, Inc.

Managing Partner at Flagship Pioneering

Paths to Denali Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Denali Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm’s investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford’s analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Details Hidden

Crestline Management has fund clients that focus on opportunistic investments and credit related investments and fund clients that focus on hedge fund investments. With respect to opportunistic and lending clients, those fund clients will make direct investments in securities, as opposed to via an investment in an underlying private fund, and certain fund clients will invest in middle market loans, whether directly-originated or syndicated loans or loans acquired in other market transactions. With respect to fund clients pursuing hedge fund strategies, Crestline Management manages an equity long/short strategy and also manages diversified hedge fund programs structured as funds of funds. Fund clients that invest in long/short equity strategies allocate assets to sector specialist portfolio managers whose stock selection is generally driven by fundamental analysis. The portfolio is run with controls on net market exposure and other risk factors. Leverage is used in the program to seek to achieve the targeted risk and return levels for the strategy. Fund clients investing in other fund managers generally allocate assets to a variety of portfolio managers through direct investments in underlying private funds or segregated portfolio arrangements, through acquisition of investments in underlying private funds managed by portfolio managers via the secondary market and, in certain instances, through discretionary managed accounts, single purpose entities, entities consisting primarily of Crestline-advised funds or through swaps or other similar products.

Details Hidden

Temasek-IM is an active, long-term manager which takes stakes in regional or global companies with significant potential. The firm aims to build companies into profitable operations while promoting sound corporate governance. They do not involve themselves in commercial or operational decisions except to exercise shareholder voting rights and help companies recruit management. Their investment decisions are taken independently of the Singapore Government. Temasek-IM has a long term investment horizon and because they invest off their own balance sheet, they are not constrained by ‘fund life’. As an owner investor, the firm is mostly invested in equities but do not set limits for geographies, sectors, or asset classes. Their global portfolio spans a broad spectrum of industries: financial services; telecommunications, media & technology; consumer & real estate; transportation & industrials; life sciences & agribusiness; as well as energy & resources. Temasek-IM invests in companies based in Singapore, Asia and the OECD countries.

Recent Transactions
Details Hidden

Denali Therapeutics, Inc. issued USD Common Stock

Details Hidden

Denali Therapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onDenali Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onDenali Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onDenali Therapeutics, Inc. issued USD Common Stock

Associate

Advised onDenali Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onDenali Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onDenali Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Venture Partner at ARCH Venture Partners

Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Clients

Biogen has some of the world’s best neurologists and neuroscientists. They engage with physicians and scientific leaders around the world with the aim to further medical research. Their focus on neuroscience, their deep scientific expertise and courage to take risks makes them leaders in the research and development of medicines to transform neuroscience to benefit society. Their technology and engineering capabilities create novel ways to seamlessly transition products from development to manufacturing with the intent of bringing their high-quality medicines to market faster. They respect the contributions of health care providers caring for people living with neurological diseases. They honor the important role of caregivers, families and friends who care about them.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Key Stats and Financials As of 2019
Market Capitalization
$8.1B
Total Enterprise Value
$1.32B
Earnings Per Share
$-2.07
Net Profit
$-198M
EBITDA
$-204M
EBITDAMargin
-763.52%
Total Debt
$72.5M
Total Equity
$395M
Enterprise Value / Sales
49.58x
TEVNet Income
-6.69x
Debt TEV
0.05x
Revenue
$26.7M
Investors
Details Hidden

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm’s investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford’s analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Details Hidden

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Details Hidden

Impresa focuses on early-stage investments in start-up companies across US and International portfolio companies. There fund focuses on companies operating in the fields of biopharmaceutical, medical technology & healthcare IT and services.There funds are larger and more global. In the US and Europe, they are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, there sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai with over $2 trillion in assets under management.

Suppliers
Roche Holding AG Medical Support Services | Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Lonza Group AG Pharmaceuticals | Basel, Che

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Centogene AG Holding Companies | Rostock, Deu

Centogene AG focuses on genetic and biochemical diagnostic testing services for rare hereditary disorders. The firm operates through the offices located in Freiburg, Dubai and Noida. The company was founded by Arndt Rolfs in 2006 and is headquartered in Rostock, Germany.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

H. Lundbeck A/S Pharmaceuticals - Valby, Denmark

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Denali Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Denali Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Denali Therapeutics, Inc..